glp·helper
glphelper.com/mounjaro/michigan/troy
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® providers &
prescriptions in Troy, MI

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Mounjaro is FDA-approved for type 2 diabetes, not for weight management.[1] The tirzepatide approved for chronic weight management is Zepbound in Troy.

Physicians near Troy, MI from the federal NPI registry. Ask each office whether it prescribes Mounjaro.[9]

city providers
17
as of today

Same molecule (tirzepatide): Tirzepatide in Troy, Zepbound in Troy

Other GLP-1 medicines: Ozempic in Troy, Wegovy in Troy, Semaglutide in Troy

§ 02Provider directory: Michigan
17 of 17 shown

Find a Mounjaro provider in Troy.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Mounjaro by Michigan town, physicians per town
§ 03Getting Mounjaro in Troy
17 providers · Troy, MI

How to get Mounjaro in Troy.

17 GLP-1 prescribers and 7 local resource types are on record for Troy, plus 3 nearby towns in the directory.

Physicians in Troy
17 physicians
17 physicians from the federal NPI registry in Troy, most listed as Internal Medicine (8), Internal Medicine, Endocrinology, Diabetes & Metabolism (5) and Family Medicine (4). A licensed clinician who evaluates you decides whether an FDA-approved GLP-1 fits. Telehealth rules vary by state. The nearest towns on record are Royal Oak (31 providers), Rochester Hills (33 providers) and Sterling Heights (29 providers).
Around the prescription in Troy
7 listed nearby
34 dietitians, 1 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 4 places to move are on record near Troy.
Medicaid (weight loss)
Limited
As of April 2026, Michigan Medicaid covers GLP-1s for weight loss only in limited cases (morbid obesity only, after other treatments fail). Diabetes coverage is broader. Employer and private plans vary by plan.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Michigan’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

Bar chart of Mounjaro dose strengths on the FDA label: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Mounjaro comes in 6 strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceMultiple (per dose)
Active ingredient
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Not FDA-approved for weight management. Zepbound is the tirzepatide approved for it
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Troy

Troy, Michigan has a population of 87,294 people. The adult obesity rate in Troy is an age-adjusted estimate of 25.9%, 10.2 percentage points below the Michigan state rate of 36.1%. Diagnosed diabetes reaches 8% of adults in Troy. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 16.8% of adults in Troy.

of Troy adults have obesity
25.9%
diagnosed diabetes
8%
no regular physical activity
16.8%

Age-adjusted estimates for Troy, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossGLP-1s and fertility
§ 05Support around Mounjaro in Troy
6 gyms

The prescription is one part. Here is the rest, in Troy.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Troy, MI, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

LA Fitness
GYM
3.2 on Google · 805 reviews
710 E Big Beaver Rd
Website
Planet Fitness
GYM
4.1 on Google · 726 reviews
288 John R Rd
Website
Life Time
GYM
3.8 on Google · 562 reviews
4700 Investment Dr
Website
Powerhouse Gym Troy
GYM
4.6 on Google · 454 reviews
2585 Livernois Rd
Website
High Caliber Strength & Fitness Troy
GYM
5.0 on Google · 331 reviews
352 Oliver
Website
Club Studio
GYM
4.0 on Google · 233 reviews
3501 E Maple Rd Ste A
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Brianna Archangeli, RD
RD
Registered dietitian
1777 Axtell Dr Ste 202
Call 248-594-3142NPI 1598437881
Lauren Baker, RD
RD
Registered dietitian
1777 Axtell Dr Ste 202
Call 248-594-3142NPI 1972148526
Kristin Black, RD
RD
Registered dietitian
1934 Livernois Rd
Call 248-686-0340NPI 1407530173
Makenna Bogaard
RD
Registered dietitian
1777 Axtell Dr Ste 202
Call 248-594-3142NPI 1235868951
Jennifer Bouren, R.D.N
RD
Registered dietitian
3311 Harmony Dr
Call 734-788-4955NPI 1073486668
Kelsey Brinton, MS, RDN
RD
Registered dietitian
192 Kirk Lane Dr
Call 989-280-9979NPI 1235815994
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8 to 2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Mounjaro weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most Mounjaro side effects are stomach and gut effects.

In Mounjaro's diabetes trials at 5 to 15 mg, the most common side effects were nausea (12 to 18%), diarrhea (12 to 17%), decreased appetite (5 to 11%), and vomiting (5 to 9%). Most reports came during dose escalation and decreased over time.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 18%
mild
Most reports came during dose escalation and decreased over time
Diarrhea
12 to 17%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
6 to 7%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

What Mounjaro costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Eli Lilly self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Mounjaro monthly cost by how you pay
Pharmacy retail (no insurance)$1,000 to $1,200per monthBrand-name retail average, May 2026[6]
LillyDirect self-payfrom $499per monthListed at the same starting price for every strength, 2.5 mg to 15 mg
Commercial insurance (T2D)$25 to $250per month copayUsually covered for diabetes with prior authorization
Medicare Part D$0 to $100per monthT2D covered; weight-loss indication not covered by law[5]
Manufacturer savings cardas low as $25per monthCommercial insurance only; eligibility limits apply
Find Mounjaro providers in Troy

Physicians from the federal NPI registry. Ask each office whether it prescribes Mounjaro.

Mounjaro in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Mounjaro.

Related GLP-1 research
§ 09Frequently asked: Mounjaro in Michigan

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]